MOLNZ Stock Overview
A clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Molecular Partners AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 4.82 |
| 52 Week High | CHF 9.49 |
| 52 Week Low | CHF 3.16 |
| Beta | 0.54 |
| 11 Month Change | -16.49% |
| 3 Month Change | -12.64% |
| 1 Year Change | 20.86% |
| 33 Year Change | -56.08% |
| 5 Year Change | n/a |
| Change since IPO | -74.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| MOLNZ | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -6.4% | 2.0% | 1.7% |
| 1Y | 20.9% | -17.5% | 8.3% |
Return vs Industry: MOLNZ exceeded the UK Biotechs industry which returned -17.5% over the past year.
Return vs Market: MOLNZ exceeded the UK Market which returned 8.3% over the past year.
Price Volatility
| MOLNZ volatility | |
|---|---|
| MOLNZ Average Weekly Movement | 13.8% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: MOLNZ's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: MOLNZ's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 162 | Patrick Amstutz | www.molecularpartners.com |
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors.
Molecular Partners AG Fundamentals Summary
| MOLNZ fundamental statistics | |
|---|---|
| Market cap | CHF 178.79m |
| Earnings (TTM) | -CHF 62.59m |
| Revenue (TTM) | CHF 6.00m |
29.8x
P/S Ratio-2.9x
P/E RatioIs MOLNZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MOLNZ income statement (TTM) | |
|---|---|
| Revenue | CHF 6.00m |
| Cost of Revenue | CHF 49.97m |
| Gross Profit | -CHF 43.96m |
| Other Expenses | CHF 18.63m |
| Earnings | -CHF 62.59m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.70 |
| Gross Margin | -732.47% |
| Net Profit Margin | -1,042.84% |
| Debt/Equity Ratio | 0% |
How did MOLNZ perform over the long term?
See historical performance and comparison